(142 days)
Not Found
Not Found
No
The summary describes a standard ELISA kit and an automated processor, neither of which are described as using AI or ML. The performance studies are based on traditional statistical analysis of assay results.
No.
This device is an in vitro diagnostic test designed to detect antibodies, aiding in the diagnosis of infectious mononucleosis, rather than providing therapy or treatment.
Yes
The "Intended Use / Indications for Use" section explicitly states that the assay should be "used... as an aid in the diagnosis of infectious mononucleosis."
No
The device is an ELISA kit, which is a laboratory assay involving physical reagents and processes, not solely software. While it can be used with an automated processor (MAGO PLUS), the core device itself is a hardware-based test kit.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states "For the qualitative determination of IgM antibodies in human serum... as an aid in the diagnosis of infectious mononucleosis." This clearly indicates the device is used to test human samples in vitro (outside the body) for diagnostic purposes.
- Device Description: The description confirms it is an "enzyme-linked immunosorbent assay (ELISA) for the detection of IgM antibodies... in human serum." This further supports its use for in vitro testing of human samples.
- Performance Studies: The performance studies describe testing "human serum" samples and evaluating the device's performance in terms of sensitivity, specificity, and agreement with characterized sera. This is typical for IVD devices.
The core function of the device is to analyze a human biological sample (serum) in vitro to provide information that aids in a medical diagnosis. This aligns perfectly with the definition of an In Vitro Diagnostic device.
N/A
Intended Use / Indications for Use
For the qualitative determination of IgM antibodies in human serum to Epstein Barr (recombinant) Viral Capsid antigen (EBV-VCA) antigen. The EBV-VCA IgM assay should be used in conjunction with other Epstein-Barr serologies (EBV-VCA IgG, EBNA-1 IgG, EA-D IgG, EA-D IgM, EBNA-1 IgM and heterophile) as an aid in the diagnosis of infectious monomucleosis. The test can be performed either manually or in conjunction with the MAGO PLUS ™ Automated EIA Processor.
Product codes
Not Found
Device Description
The & EBV-VCA IgM ELISA Kit is an enzyme-linked immunosorbent assay (ELISA) for the detection of IgM antibodies to Epstein-Barr Viral Capsid antigen in human serum.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Frozen retrospective sera from one hundred and seventy-six patients were characterized using commercially available kits for VCA IgM, VCA IgG, EBNA IgG and heterophile antibodies.
Summary of Performance Studies
Clinical Sensitivity and Specificity Using Characterized Sera:
Study type: Clinical evaluation
Sample size: 176 sera
Key results:
- Relative Specificity (Convalescent): 98/101 = 97.0% (95% CI: 91.6-99.4)
- Relative Sensitivity (Current Infection): 38/40 = 95.0% (95% CI: 83.1-99.4)
- Relative Specificity (Seronegative): 32/32 = 100% (95% CI: 89.1-100)
- Overall Agreement: 168/173 = 97.1% (95% CI: 93.4-99.1)
Note: Equivocal results were excluded from calculations. "Relative" refers to comparison with a similar assay, not disease presence/absence correlation.
Precision:
Study type: Multi-site precision study
Sample size: Four positive and two negative sera, assayed ten times each in three different runs at three different sites (manufacturer, research and development laboratory, clinical commercial laboratory).
Key results: Intra-assay and interassay precision were determined for each site, and inter-site precision was also evaluated. CV% values varied depending on the serum sample and assay conditions, generally showing good precision.
Specificity with Potentially Cross-Reactive Sera:
Study type: Cross-reactivity
Sample size: Thirteen sera, reactive for IgM antibodies to varicella zoster, cytomegalovirus, and herpes simplex virus by EIA.
Key results:
- 3/4 anti-VZV IgM positive sera were non-reactive for anti-VCA IgM.
- 3/5 anti-CMV IgM positive sera were non-reactive for anti-VCA IgM.
- 4/4 anti-HSV positive sera were non-reactive for anti-VCA IgM.
This suggests that some specific cross-reactivity should be expected with the Is-VCA IgM Test Kit from these analytes.
Correlation of Manual and MAGO Plus Results:
Study type: Method comparison
Sample size: 120 serum samples
Key results: Pearson Correlation Coefficient of 0.990, indicating good correlation between manual and MAGO Plus procedures.
MAGO Plus Precision:
Study type: Automated precision study
Sample size: Six sera, assayed ten times each in three different runs on the MAGO Plus Automated EIA Processor.
Key results: Intra- and interassay precision obtained using the MAGO Plus were determined, showing varying CV% values for different serum samples.
Key Metrics
Relative Specificity (Convalescent) 98/101 = 97.0%
Relative Sensitivity (Current Infection) 38/40 = 95.0%
Relative Specificity (Seronegative) 32/32 = 100%
Overall Agreement 168/173 = 97.1%
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.3235 Epstein-Barr virus serological reagents.
(a)
Identification. Epstein-Barr virus serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to Epstein-Barr virus in serum. The identification aids in the diagnosis of Epstein-Barr virus infections and provides epidemiological information on diseases caused by these viruses. Epstein-Barr viruses are thought to cause infectious mononucleosis and have been associated with Burkitt's lymphoma (a tumor of the jaw in African children and young adults) and postnasal carcinoma (cancer).(b)
Classification. Class I (general controls).
0
NOV 2 5 1998
16982352
510k Summary of Safety and Effectiveness
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is:
Applicant Information:
| Date Prepared: | June 11, 1998 |
|---|---|
| Name: | Columbia Bioscience, Inc. |
| Address: | 8775 M Centre Park Drive, #559 |
| Columbia, MD 21045 |
| Contact Person: | Norman Jenkins |
|---|---|
| PhoneNumber: | 410-995-0450 |
| Fax Number: | 410-995-0448 |
Device Information:
| Trade Name: | EBV-VCA IgM ELISA Kit |
|---|---|
| Common Name. | EBV-VCA IgM EIA Test |
| Classification Name; | Epstein-Barr Virus |
Equivalent Device: EBV Serology
Device Description: The & EBV-VCA IgM ELISA Kit is an enzyme-linked immunosorbent assay (ELISA) for the detection of IgM antibodies to Epstein-Barr Viral Capsid antigen in human serum.
Intended Use: For the qualitative determination of IgM antibodies in human serum to Epstein Barr (recombinant) Viral Capsid antigen (EBV-VCA) antigen. The EBV-VCA IgM assay should be used in conjunction with other Epstein-Barr serologies (EBV-VCA IgG, EBNA-1 IgG, EA-D IgG, EA-D IgM, EBNA-1 IgM and heterophile) as an aid in the diagnosis of infectious monomucleosis. The test can be performed either manually or in conjunction with the MAGO PLUS ™ Automated EIA Processor.
Principle of Procedure:
The & EBV-VCA IgM ELISA Kit is an enzyme-linked immunosorbent assay to detect IgM to EBV-VCA in human serum. Recombinant EBV-VCA antigen is attached to a solid phase (microtiter well). Diluted test sera are added to each well. If antibodies which recognize the EBV-VCA antigen are present in the patient sample they will bind to the antigen in the well. After incubation, the wells are washed to remove unbound antibody. An enzyme labeled anti-human immunoglobulin (conjugate) is added to each test well. If antibody is present the enzyme-linked antibody will bind to it. After incubation, the wells are washed to remove unbound conjugate. A substrate solution is then added to each well. If enzyme is present from prior step, the reaction is stopped and the color intensity is measured photometrically producing an indirect detection of the specific antibody present in the patient sample.
1
Performance Characteristics
A. Clinical Sensitivity and Specificity Using Characterized Sera
Frozen retrospective sera from one hundred and seventy-six patients were characterized using commercially available kits for VCA IgM, VCA IgG, EBNA IgG and heterophile antibodies. Based on the results of this testing, the patient sera were characterized as follows:
-
- 102 sera were characterized as convalescent (past infection). These were positive for VCA IgG and/or EBNA IgG antibodies and negative for VCA IgM and heterophile antibody.
-
- 32 scra were characterized as scronegative. These were negative for VCA IgG, VCA IgM, EBNA IgG and beterophile antibody.
-
- 42 sera were characterized as having a current (recent) infection. These were positive for VCA IgM and/or heterophile antibody and were negative for EBNA IgG.
All 176 sera were then tested by an independent clinical commercial laboratory using the Is-EBV-VCA IgM Test Kit. The results obtained are shown in Table 2:
| EBV Serological Status | ||||
|---|---|---|---|---|
| Convalescent | Current Infection | Seronegative | ||
| POSITIVE | 3 | 38 | 0 | |
| Is-EBV-VCA IgM | NEGATIVE | 98 | 2 | 32 |
| *EQUIVOCAL | 1 | 2 | 0 | |
| Relative Specificity (Convalescent) 98/101 = 97.0% | 95% CI | |||
| 91.6-99.4 | ||||
| Relative Sensitivity (Current Infection) 38/40 = 95.0% | 83.1-99.4 | |||
| Relative Specificity (Seronegative) 32/32 = 100% | 89.1-100 | |||
| Overall Agreement 168/173 = 97.1% | 93.4-99.1 |
- Equivocal results were excluded from calculations
NOTE : Please be advised that 'relative' refers to the comparison of the assay's results to that of a similar assay. There was not an attempt to correlate the assay's results with disease presence or absence. No judgment can be made on the comparison's accuracy to predict disease. Since the above studies were performed on a pre-selected, retrospective, population, no calculations for the assay's positive predictive value may be done or inforred.
2
B. Precision
To determine the precision of the Is-EBV-VCA IgM Test Kit, four positive and two negative sera were assayed ten times each in three different runs at three different sites. The 3 sites include: the manufacturer, a research and develooment laboratory, and a clinical commercial laboratory. The intra- and interassay precision obtained at each site is shown in Tables 3, 4 and 5. The Inter-Site precision is shown in Table 6.
TABLE 3 : Site #1 - Intra-Assay and Interassay Precision
| SERUM | MEAN
INDEX | INTRA-ASSAY RUN 1
CV% | MEAN
INDEX | INTRA-ASSAY RUN 2
CV% | MEAN
INDEX | INTRA-ASSAY RUN 3
CV% | MEAN
INDEX | INTERASSAY
CV% | |
|---------|---------------|--------------------------|---------------|--------------------------|---------------|--------------------------|---------------|-------------------|-------|
| A (POS) | 1.41 | 8.08 | 1.77 | 6.07 | 1.67 | 8.45 | 1.62 | 12.05 | |
| B (POS) | 2.17 | 7.97 | 2.78 | 7.01 | 2.35 | 6.26 | 2.44 | 12.67 | |
| C (POS) | 4.01 | 9.92 | 5.05 | 7.15 | 4.22 | 6.78 | 4.43 | 12.86 | |
| D (POS) | 2.70 | 8.91 | 3.32 | 13.74 | 2.81 | 4.35 | 2.94 | 13.69 | |
| E (NEG) | 0.35 | 17.21 | 0.54 | 8.51 | 0.45 | 21.03 | 0.44 | 22.75 | |
| F (NEG) | 0.09 | 49.37 | 0.17 | 26.31 | 0.18 | 14.93 | 0.14 | 39.31 | |
| | | | | | | | CAL | 1.03 | 10.81 |
| | | | | | | | PC | 1.59 | 25.45 |
| | | | | | | | NC | 0.49 | 18.70 |
TABLE 4 : Site #2- Intra-Assay and Interassay Precision
| SERUM | INTRA-ASSAY RUN 1 | INTRA-ASSAY RUN 2 | INTRA-ASSAY RUN 3 | INTERASSAY | ||||
|---|---|---|---|---|---|---|---|---|
| MEAN | ||||||||
| INDEX | CV% | MEAN | ||||||
| INDEX | CV% | MEAN | ||||||
| INDEX | CV% | MEAN | ||||||
| INDEX | CV% | |||||||
| A (POS) | 1.47 | 3.96 | 1.34 | 4.14 | 1.31 | 4.13 | 1.37 | 6.53 |
| B (POS) | 2.25 | 6.35 | 1.99 | 4.31 | 2.06 | 4.90 | 2.10 | 7.34 |
| C (POS) | 3.92 | 3.95 | 3.45 | 2.43 | 3.50 | 4.35 | 3.62 | 6.96 |
| D (POS) | 2.57 | 6.26 | 2.26 | 5.36 | 2.41 | 3.06 | 2.41 | 7.31 |
| E (NEG) | 0.35 | 7.41 | 0.32 | 8.33 | 0.33 | 11.03 | 0.33 | 9.38 |
| F (NEG) | 0.14 | 17.42 | 0.12 | 10.23 | 0.12 | 9.31 | 0.12 | 14.80 |
| CAL | 1.00 | 3.79 | ||||||
| PC | 1.43 | 3.91 | ||||||
| NC | 0.19 | 22.90 |
| TABLE 5 : Site #3 - Intra-assay and Interassay Precision | |||
|---|---|---|---|
| -- | -- | -- | ---------------------------------------------------------- |
| SERUM | INTRA-ASSAY RUN 1 | INTRA-ASSAY RUN 2 | INTRA-ASSAY RUN 3 | INTERASSAY | |||||
|---|---|---|---|---|---|---|---|---|---|
| MEAN INDEX | CV% | MEAN INDEX | CV% | MEAN INDEX | CV% | MEAN INDEX | CV% | ||
| A (POS) | 1.48 | 4.94 | 1.43 | 4.97 | 1.48 | 5.15 | 1.46 | 5.08 | |
| B (POS) | 2.19 | 6.22 | 2.20 | 6.44 | 2.13 | 4.55 | 2.17 | 5.80 | |
| C (POS) | 3.78 | 5.99 | 3.58 | 4.80 | 3.70 | 5.25 | 3.68 | 5.69 | |
| D (POS) | 2.64 | 5.67 | 2.52 | 5.75 | 2.56 | 4.15 | 2.57 | 5.40 | |
| E (NEG) | 0.45 | 12.82 | 0.38 | 9.77 | 0.40 | 10.27 | 0.41 | 13.26 | |
| F (NEG) | 0.20 | 9.43 | 0.16 | 7.16 | 0.18 | 11.82 | 0.18 | 12.70 | |
| CAL | 1.00 | 3.22 | n=9 | ||||||
| PC | 1.21 | 3.74 | n=3 | ||||||
| NC | 0.62 | 1.85 | n = 3 |
| TABLE 6 : Inter-Site Precision | ||||||
|---|---|---|---|---|---|---|
| -- | -- | -- | -- | -- | -- | -------------------------------- |
| SERUM
| (n=90) | INTER-SITE | |
|---|---|---|
| MEAN | ||
| INDEX | CV% | |
| A (POS) | 1.48 | 11.13 |
| B (POS) | 2.24 | 11.41 |
| C (POS) | 3.91 | 13.43 |
| D (POS) | 2.64 | 13.09 |
| E (NEG) | 0.40 | 20.69 |
| F (NEG) | 0.15 | 28.77 |
| CAL (n=36) | 1.01 | 6.22 |
| LPC (n=18) | 1.42 | 13.16 |
| NC (n=18) | 0.31 | 60.11 |
3
C. Specificity with Potentially Cross-Reactive Sera
Thirteen scra, reactive for IgM antibodies to varicella zoster, cylomegalovirus and herpes simplex virus by EIA were cested in the Is-EBV-VCA IgM Test Kit. 3/4 anti-VZV IgM positive sera were non-reactive for anti-VCA IgM; 3/5 anti-CMV IgM positive scra were non-reactive for anti-VCA IgM and 4/4 anti-HSV positive scra were non-reactive for anti-VCA IgM. This suggests that some specific cross-reactivity should be expected with the Is-VCA IgM Test Kit from these analytes.
D. Correlation of Manual and MAGO Plus Results
The Is-EBV-VCA IgM Test Kit has been developed for automated as well as manual use. To demonstrate the equivalence of the manual and MAGO Plus procedures, the results of 120 serum samples tested by both methods were plotted. A scattergram and regression line of the results obtained with 95% confidence intervals is shown in Figure 3. The data indicate good correlation with a Pearson Correlation Coefficient of 0.990.
Image /page/3/Figure/4 description: The image is a scatter plot comparing MAGO PLUS INDEX VALUES to MANUAL INDEX VALUES. The x-axis represents MANUAL INDEX VALUES, ranging from 0 to 7, while the y-axis represents MAGO PLUS INDEX VALUES, ranging from -0.5 to 5.5. The plot includes a regression line with the equation Y = 0.0045 + 0.7074X, and the correlation coefficient r is 0.990, indicating a strong positive correlation between the two variables.
FIGURE 3 : Manual and MAGO Plus Result Correlation
D. MAGO Plus Precision
The precision of the assay when performed on the MAGO Plus Automated EIA Processor was determined by assaying six sera ten times each in three different runs. Table 7 shows the intra-and interassay precision obtained using the MAGO Plus.
| SERUM | INTRA-ASSAY RUN 1 | INTRA-ASSAY RUN 2 | INTRA-ASSAY RUN 3 | INTERASSAY | |||||
|---|---|---|---|---|---|---|---|---|---|
| MEAN | CV% | MEAN | CV% | MEAN | CV% | MEAN | CV% | ||
| INDEX | INDEX | INDEX | INDEX | ||||||
| A (POS) | 1.15 | 4.58 | 1.28 | 7.18 | 1.16 | 9.27 | 1.20 | 8.64 | |
| B (POS) | 1.74 | 5.55 | 1.80 | 6.42 | 1.69 | 7.08 | 1.74 | 6.68 | |
| C (POS) | 3.19 | 4.30 | 3.34 | 4.72 | 3.22 | 3.53 | 3.25 | 4.55 | |
| D (POS) | 1.96 | 4.93 | 2.07 | 6.85 | 2.06 | 5.22 | 2.03 | 6.09 | |
| E (NEG) | 0.28 | 22.59 | 0.31 | 10.20 | 0.29 | 19.57 | 0.29 | 17.76 | |
| F (NEG) | 0.10 | 0.00 | 0.10 | 0.00 | 0.10 | 0.00 | 0.10 | 0.00 | |
| CAL | 1.00 | 4.54 | n=S | ||||||
| PC | 1.26 | 3.20 | n = 3 | ||||||
| NC | 0.39 | 9.08 | n = 3 |
TABLE 7 : Site #2- Intra-Assay and Interassay Precision - MAGO Plus
4
Image /page/4/Picture/1 description: The image shows the logo for the Department of Health & Human Services USA. The logo consists of a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES USA" written around it. Inside the circle is an abstract symbol that resembles an eagle or a bird in flight, composed of three curved lines.
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
NOV 2 5 1998
Norman Jenkins President Columbia Bioscience, Inc. 8775 M Centre Park Drive, #559 Columbia, Maryland 21045
Re: K982352 Device: VCA IgM ELISA Test System Dated: September 22, 1998 Received: September 28, 1998
Dear Mr. Jenkins:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (OS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
5
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770)488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll free number (800) 638-2041 or at (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsmamain.html"
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
6
Page 1 of 1
510(k) Number: Not Known
Device Name: 7 VCA IgM ELISA
Indications For Use: For the qualitative determination of IgM antibodies in human serum to Epstein Barr (recombinant) Viral Capsid antigen (VCA) antigen. The 78 VCA IgM assay should be used in conjunction with other Epstein-Barr serologies (VCA IgG, EBNA-1 IgG, EA-D IgM, EA-D IgG, EBNA-1 IgM and heterophile) as an aid in the diagnosis of infectious mononucleosis. The test can be performed either manually or in conjunction with the MAGO PLUS TM Automated EIA Processor
PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) 】 【 【 】 】
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use X (Per 21 CFR 801.109) OR
Over-The Counter Use (Optional Format 1-2-96)
Woody Dubois
Division of Clinical Laboratory Devices 510(k) Number_1 982352